Skip to main content
. Author manuscript; available in PMC: 2024 Nov 11.
Published in final edited form as: J Thromb Haemost. 2022 Dec 22;21(3):586–598. doi: 10.1016/j.jtha.2022.11.022

FIGURE 2.

FIGURE 2

Endotoxemia increases thrombosis incidence, an outcome that is mitigated by reduced VWF activity. (A) Thrombus incidence and (B) thrombus weights (>0 mg) of vehicle control and LPS-treated mice at 24 hours post-stenosis. (C) VWF:GPIbM at 24 hours post-stenosis in vehicle control and LPS-treated mice treated with αVWF antibody (n = 10 and n = 8, respectively) or ISO (n = 6 and n = 9, respectively), expressed as a percentage of activity relative to pooled murine plasma as reference. (D) Thrombus incidence and (E) thrombus weights in control and LPS-treated mice in αVWF and ISO cohorts at 24 hours post-stenosis. ns: not significant. *p < .05, ***p < .001. ISO, isotope control antibody; LPS, Lipopolysaccharide; ns, not significant; VWF:Ag, plasma von Willebrand factor; VWF:CB, von Willebrand factor–collagen binding activity; VWF:GbIb, VWF-GPIb binding activity.